The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular drugs like Elismetrep and Dysport, are expected to reshape the market. The U.S. leads in market size, with significant advances in both acute and preventive migraine therapies. These developments promise improved patient outcomes and new opportunities for pharmaceutical innovation.
The migraine market's expected growth and novel therapies provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 23:22 WIB: out of 150 priced US health-sector stocks, 77 rose and 70 fell. Notable movers include SYRE (Spyre Therapeutics Inc.) at USD 84.61 with a 1-day change of +5.89% and a typical hold time of 4 days, DYN (Dyne Therapeutics Inc.) at USD 15.06 with +5.68% change and a 3-day hold, and TWST (Twist Bioscience Corp) at USD 139.70 with +5.24% change and a 27-day hold.
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
